In principle, I would not. However, on a case-by-case analysis, it can be an interesting option.
For example, Pluristem is growing placenta-derived stem cells in a fixed-bed bioreactor, and it was able to scale them up to quite a large scale with huge benefits because the microcarrier development was avoided.
Another example is insect cells; we know that Sf9 can grow entrapped in a fixed-bed bioreactor and that recovery is very easy.